ANI delivered record Q4 2025 revenue of 247060000, up 29.6% year-over-year, with strong Cortrophin Gel and Generics growth driving profitability. Net income available to common shareholders was 27490000 and adjusted non-GAAP EBITDA rose 30.6% to 65356000.

ANI Pharmaceuticals delivered record Q3 2025 revenue of $227.8 million and adjusted non-GAAP EPS of $2.04. Performance was driven by exceptional Cortrophin Gel sales and continued momentum in Generics. Net income reached $26.3 million, and the company raised full-year guidance on both revenue and earnings.

ANI Pharmaceuticals delivered record Q2 2025 revenue of $211.4M, up 53% year-over-year, driven by strong performance in Rare Disease, particularly Cortrophin Gel, and solid Generics growth. Adjusted non-GAAP EPS reached $1.80 and adjusted EBITDA rose 63% to $54.1M. The company raised full-year guidance for revenue, adjusted EBITDA, and adjusted EPS.

ANI Pharmaceuticals reported record financial results for the first quarter of 2025, including record net revenues, adjusted EBITDA, and adjusted EPS. Performance was driven by strong demand for Cortrophin Gel and exceptional growth in the Generics business, leading the company to raise its full-year 2025 guidance.

ANI Pharmaceuticals reported record Q4 2024 financial results, with a 44.8% increase in total net revenues to $190.6 million. The company's Rare Disease segment, including Cortrophin Gel, ILUVIEN, and YUTIQ, significantly contributed to this growth. Adjusted non-GAAP EBITDA increased by 65.7% to $50.0 million, and adjusted non-GAAP diluted earnings per share reached $1.63.

ANI Pharmaceuticals reported record third-quarter net revenues of $148.3 million, a 12.5% year-over-year increase, and record Purified Cortrophin Gel net revenues of $52.6 million, a 76.8% year-over-year increase. The company reported a net loss of $(24.2) million and adjusted non-GAAP EBITDA of $35.1 million. Diluted GAAP loss per share was $(1.27), and adjusted non-GAAP diluted earnings per share was $1.34. ANI completed the acquisition of Alimera Sciences and increased its 2024 guidance.

ANI Pharmaceuticals reported record quarterly net revenues of $138.0 million, representing year-over-year growth of 18.4%, and record Rare Disease net revenues of $49.2 million, an increase of 102.4% year-over-year. The company delivered adjusted non-GAAP diluted earnings per share of $1.02. ANI increased 2024 guidance with expected net revenues of $540 million to $560 million, adjusted non-GAAP EBITDA of $140 million to $150 million and adjusted non-GAAP earnings per share of $4.38 to $4.82.

ANI Pharmaceuticals is focusing on its rare disease business, particularly Purified Cortrophin® Gel, as a primary growth driver. The company is expanding its rare disease platform through strategic initiatives, including M&A and in-licensing, and is targeting key therapeutic areas such as nephrology, neurology, rheumatology, pulmonology, and ophthalmology to increase its market presence and revenue.

ANI Pharmaceuticals reported a strong fourth quarter and record full-year financial results for 2023. Q4 net revenues reached $131.7 million, a 39.7% increase year-over-year, with net income of $0.7 million and GAAP diluted earnings per share of $0.04. The Rare Disease business, led by Cortrophin Gel, saw substantial growth, and the company issued 2024 revenue guidance of $520 million to $542 million.

ANI Pharmaceuticals reported strong Q3 2023 results, with a 57% increase in revenues to $132 million and a 119% increase in diluted non-GAAP EPS to $1.27. The company's growth was driven by its Rare Disease business, Generics, and Established Brands.

ANI Pharmaceuticals reported a strong second quarter with record net revenues of $116.5 million, representing a 57.8% year-over-year growth. The company's lead rare disease asset, Purified Cortrophin® Gel, saw a 138.2% increase in net sales, and Generics, Established Brands and Others reported a 44.9% growth. The company raised its full-year 2023 guidance for net revenue, adjusted non-GAAP EBITDA, and adjusted non-GAAP earnings per share.

ANI Pharmaceuticals reported record first-quarter 2023 financial results, with net revenues reaching $106.8 million, a 65.6% year-over-year increase. The company's net income available to common shareholders was $1.0 million, with a diluted GAAP income per share of $0.06. Adjusted non-GAAP EBITDA reached $33.0 million, and adjusted non-GAAP diluted earnings per share was $1.17. The company also raised its full-year 2023 guidance for net revenue, adjusted non-GAAP EBITDA, and adjusted non-GAAP earnings per share.

ANI Pharmaceuticals reported Q4 net revenues of $94.2 million, a net loss available to common shareholders of $(4.7) million, and an adjusted non-GAAP diluted earnings per share of $0.76. The company's full-year 2022 net revenues reached $316.4 million.

ANI Pharmaceuticals reported record net revenues of $83.8 million, a 61% year-over-year increase. The company is maintaining its 2022 revenue guidance of $295 million to $315 million and adjusted non-GAAP EBITDA guidance of $54 million to $60 million.

ANI Pharmaceuticals reported a record-breaking second quarter with net revenues of $73.9 million, driven by Purified Cortrophin® Gel sales and growth in generic pharmaceuticals. The company raised its full-year 2022 net revenue guidance for Purified Cortrophin® Gel.

ANI Pharmaceuticals reported first quarter net revenues of $64.5 million and a net loss of $(20.1) million, with a diluted GAAP loss per share of $(1.27). The company launched Cortrophin Gel and is increasing its full-year net revenue guidance.

ANI Pharmaceuticals reported third quarter results with net revenues of $52.1 million and a net loss of $4.4 million. The company highlights the FDA approval of the supplemental new drug application for Purified Cortrophin™ Gel and the expected acquisition of Novitium Pharma LLC.

ANI Pharmaceuticals reported second quarter net revenues of $48.6 million, a net loss of $14.1 million, and adjusted non-GAAP diluted earnings per share of $0.67. The company refiled its sNDA for Cortrophin Gel with the FDA and is on track to close the acquisition of Novitium Pharma LLC in the second half of 2021. They also expanded their branded products portfolio through the acquisition of Sandoz Inc. NDAs.

ANI Pharmaceuticals reported first quarter 2021 results with net revenues of $54.5 million and net income of $0.1 million. The company is progressing with the Cortrophin Gel sNDA re-filing and the acquisition of Novitium Pharma, while also expanding its branded products portfolio.

ANI Pharmaceuticals reported Q4 2020 net revenues of $57.3 million, a net loss of $3.6 million, and a diluted loss per share of $0.30. The company's adjusted non-GAAP diluted EPS was $0.80. ANI is focused on sustainable future growth and has strengthened its capital structure through the acquisition of Novitium Pharma.

ANI Pharmaceuticals reported third quarter 2020 results with net revenues of $53.0 million, a net income of $0.4 million, and diluted EPS of $0.04. The company is on track with the Cortrophin® Gel sNDA re-filing and has a commercialization and operational launch readiness plan underway. A new CEO and Board members have been added to drive business growth.

ANI Pharmaceuticals reported a decrease in net revenues to $48.5 million for the second quarter of 2020, compared to $54.5 million in the same period of 2019. The company experienced a net loss of $12.3 million, compared to a net income of $6.6 million in the prior year period. Adjusted non-GAAP diluted earnings per share was $0.69, down from $1.44 in the second quarter of 2019. The results were impacted by the COVID-19 pandemic and increased operating expenses.

ANI Pharmaceuticals reported net revenues and non-GAAP earnings that met management's expectations, launched five generic products, and integrated the Amerigen Pharmaceuticals, Ltd. portfolio. However, the company experienced a net loss and decreased earnings per share compared to the prior year period and suspended its 2020 financial guidance due to COVID-19 uncertainties.

ANI Pharmaceuticals reported a net loss of $4.8 million for Q4 2019, driven by Cortrophin pre-launch commercial inventories and inventory reserve charges. Adjusted non-GAAP diluted earnings per share was $1.08. The company is on track to submit its Cortrophin® Gel sNDA to the FDA in March 2020.